You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Japanese regulators have approved Daiichi Sankyo's trastuzumab deruxtecan (Enhertu), a HER2-targeted antibody drug conjugate, for chemotherapy-treated, unresectable or recurrent breast cancer patients.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.